US Stock MarketDetailed Quotes
VSTM Verastem
- 5.3400
- +0.7700+16.85%
Close Nov 29 13:00 ET
- 5.3200
- -0.0200-0.37%
Post 17:01 ET
237.66MMarket Cap-1700P/E (TTM)
5.4850High4.6100Low1.54MVolume4.6100Open4.5700Pre Close7.88MTurnover5.06%Turnover RatioLossP/E (Static)44.51MShares14.220052wk High21.45P/B162.22MFloat Cap2.100052wk Low--Dividend TTM30.38MShs Float225.8400Historical High--Div YieldTTM19.15%Amplitude2.1000Historical Low5.1240Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Verastem Stock Forum
If you had bought on 10/31 my last comment, you'd be up 30% now, grats
Pretty damn good run so far. I only managed to hop on in Sept.
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
No comment yet